Brokerages forecast that Recro Pharma Inc (NASDAQ:REPH) will post sales of $24.06 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Recro Pharma’s earnings, with the lowest sales estimate coming in at $22.70 million and the highest estimate coming in at $26.32 million. Recro Pharma posted sales of $21.74 million in the same quarter last year, which suggests a positive year over year growth rate of 10.7%. The business is expected to report its next quarterly earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that Recro Pharma will report full year sales of $91.91 million for the current financial year, with estimates ranging from $86.60 million to $100.95 million. For the next year, analysts expect that the business will post sales of $96.96 million, with estimates ranging from $87.60 million to $106.00 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Recro Pharma.
Recro Pharma (NASDAQ:REPH) last announced its earnings results on Friday, May 10th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.69. Recro Pharma had a negative net margin of 83.56% and a negative return on equity of 654.93%. The business had revenue of $25.07 million during the quarter, compared to analysts’ expectations of $20.51 million.
A number of equities research analysts have recently commented on REPH shares. Janney Montgomery Scott reaffirmed a “buy” rating and issued a $13.00 target price on shares of Recro Pharma in a report on Thursday, January 31st. Oppenheimer set a $18.00 target price on shares of Recro Pharma and gave the company a “buy” rating in a report on Wednesday, February 20th. Zacks Investment Research cut shares of Recro Pharma from a “strong-buy” rating to a “hold” rating in a report on Saturday, February 23rd. Roth Capital reiterated a “neutral” rating and set a $7.50 price target (down from $15.00) on shares of Recro Pharma in a research note on Monday, March 25th. Finally, ValuEngine lowered shares of Recro Pharma from a “buy” rating to a “hold” rating in a research note on Monday, March 25th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $10.95.
Shares of NASDAQ:REPH traded up $0.14 on Thursday, reaching $9.13. The company’s stock had a trading volume of 203,400 shares, compared to its average volume of 360,620. Recro Pharma has a 52-week low of $4.78 and a 52-week high of $13.05. The company has a debt-to-equity ratio of 4.04, a quick ratio of 2.08 and a current ratio of 3.56. The stock has a market capitalization of $199.41 million, a price-to-earnings ratio of -3.67 and a beta of -0.13.
In related news, Director Arnaud Ajdler bought 40,000 shares of the stock in a transaction on Friday, May 17th. The shares were bought at an average cost of $9.00 per share, for a total transaction of $360,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Geraldine Henwood sold 144,806 shares of the company’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $8.89, for a total transaction of $1,287,325.34. Following the transaction, the chief executive officer now owns 342,947 shares in the company, valued at $3,048,798.83. The disclosure for this sale can be found here. Insiders own 20.10% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. grew its position in shares of Recro Pharma by 5.7% in the fourth quarter. BlackRock Inc. now owns 1,154,815 shares of the specialty pharmaceutical company’s stock valued at $8,199,000 after purchasing an additional 62,787 shares during the last quarter. Engine Capital Management LP grew its position in shares of Recro Pharma by 22.0% in the first quarter. Engine Capital Management LP now owns 1,064,546 shares of the specialty pharmaceutical company’s stock valued at $6,238,000 after purchasing an additional 192,052 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Recro Pharma by 21.5% in the first quarter. Renaissance Technologies LLC now owns 742,200 shares of the specialty pharmaceutical company’s stock valued at $4,349,000 after purchasing an additional 131,400 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Recro Pharma by 126.0% in the first quarter. The Manufacturers Life Insurance Company now owns 605,301 shares of the specialty pharmaceutical company’s stock valued at $3,547,000 after purchasing an additional 337,468 shares during the last quarter. Finally, Kennedy Capital Management Inc. grew its position in shares of Recro Pharma by 19.5% in the first quarter. Kennedy Capital Management Inc. now owns 598,107 shares of the specialty pharmaceutical company’s stock valued at $3,505,000 after purchasing an additional 97,482 shares during the last quarter. Institutional investors own 56.12% of the company’s stock.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Featured Article: The benefits and drawbacks of dollar cost averaging
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.